Spotlight on Hematology
Current and Emerging Therapies for Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
StartActivity Details
Expires: September 22, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Transplantation, hematology, and hematology/oncology clinicians engaged in the care of patients with GVHD.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Utilize available therapeutic strategies for the prevention and treatment of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (alloHSCT)
- Implement current and emerging strategies to address unmet needs in the management of steroid-refractory acute GVHD in allogeneic HSCT
Activity Description
Allogeneic HSCT is a revolutionary therapeutic discovery, yet despite advances, the procedure still carries substantial risk for complications and death. Even with prophylactic measures, many patients will go on to develop acute graft-versus-host disease (aGVHD). While there are several agents available for the prevention and treatment of aGVHD, there are still many unmet needs. In this Clinical Reflections® activity, learners will be presented with 2 cases of aGVHD and challenged by expert faculty to reflect back on how they could have been better managed. Faculty will then discuss current guidelines; prevention and treatment options; and emerging agents for prevention, first-line therapy, and steroid-refractory aGVHD.
Faculty
Associate Professor, Medicine
Hematology/Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Assistant Professor, Pediatrics
Harvard Medical School
Medical Director, Clinical Research and Clinical Development
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, MA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Christine N. Duncan, MD, has relevant financial relationships with bluebird bio, Inc., Jazz Pharmaceuticals, Magenta Therapeutics, Novartis, Omeros, Tome Biosciences (Consultant).
Doris M. Ponce, MD, has relevant financial relationships with Incyte Corporation, Kadmon Corporation (Advisor); CareDx, Ceramedix, Evive Biotech, Kadmon Corporation (Consultant); Incyte Corporation (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support of improving
patient care, RMEI Medical Education, LLC is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from CSL Behring LLC.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Activity Details
Expires: September 22, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Transplantation, hematology, and hematology/oncology clinicians engaged in the care of patients with GVHD.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Utilize available therapeutic strategies for the prevention and treatment of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (alloHSCT)
- Implement current and emerging strategies to address unmet needs in the management of steroid-refractory acute GVHD in allogeneic HSCT
Activity Description
Allogeneic HSCT is a revolutionary therapeutic discovery, yet despite advances, the procedure still carries substantial risk for complications and death. Even with prophylactic measures, many patients will go on to develop acute graft-versus-host disease (aGVHD). While there are several agents available for the prevention and treatment of aGVHD, there are still many unmet needs. In this Clinical Reflections® activity, learners will be presented with 2 cases of aGVHD and challenged by expert faculty to reflect back on how they could have been better managed. Faculty will then discuss current guidelines; prevention and treatment options; and emerging agents for prevention, first-line therapy, and steroid-refractory aGVHD.
Faculty
Associate Professor, Medicine
Hematology/Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Assistant Professor, Pediatrics
Harvard Medical School
Medical Director, Clinical Research and Clinical Development
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, MA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Christine N. Duncan, MD, has relevant financial relationships with bluebird bio, Inc., Jazz Pharmaceuticals, Magenta Therapeutics, Novartis, Omeros, Tome Biosciences (Consultant).
Doris M. Ponce, MD, has relevant financial relationships with Incyte Corporation, Kadmon Corporation (Advisor); CareDx, Ceramedix, Evive Biotech, Kadmon Corporation (Consultant); Incyte Corporation (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support of improving
patient care, RMEI Medical Education, LLC is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from CSL Behring LLC.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Hematology Presentations
Exploiting BCMA in the Treatment of Multiple Myeloma: How Could Bispecific Antibodies and T-Cell Engagement Impact Relapsed/Refractory Disease? Proceedings from a Clinical Olympics℠
StartActivity Details
1.0 ANCC Contact Hour(s)
Expires: January 29, 2024
Provided By
RMEI Medical Education, LLC
Target Audience
Medical oncologists, hematologists, hematologist-oncologists, pathologists, and oncology nurses
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Select an appropriate B cell maturation antigen (BCMA) targeted therapy among approved options for patients with relapsed/refractory (R/R) multiple myeloma (MM)
- Integrate novel BCMA-targeted therapies into the treatment paradigm of R/R MM, with an emphasis on bispecific antibodies
- Manage adverse events (AEs) associated with BCMA-directed therapies in patients with R/R MM
Activity Description
The advent of BCMA-directed therapy fills a significant gap in the treatment of relapsed/refractory multiple myeloma. As the field rapidly evolves, clinicians are challenged to navigate an increasingly complex therapeutic landscape. In this clinically relevant, high-level activity, Dr. Sundar Jagannath, Dr. María-Victoria Mateos, and Dr. James Hoffman provide privileged insights into optimal selection and integration of BCMA-directed therapies, particularly bispecific antibodies, to maximize patient outcomes.
Chair
Chair, Multiple Myeloma
Professor, Medicine
Icahn School of Medicine at Mount Sinai
Director, Multiple Myeloma Center of Excellence
Tisch Cancer Center Institute
Editor-in-Chief, Clinical Lymphoma, Myeloma & Leukemia
Mount Sinai Hospital
New York, NY
Faculty
Associate Professor, Clinical Medicine
Division of Myeloma (Hematology)
Sylvester Comprehensive Cancer Center (SCCC)
University of Miami
Miami, FL
Associate Professor, Hematology
Director, Myeloma Program
University Hospital of Salamanca
Salamanca, Spain
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
James Hoffman, MD, has relevant financial relationships with Bristol Myers Squibb (Speaker/Speaker’s Bureau).
Sundar Jagannath, MD, FASCO, has relevant financial relationships with Epizyme, Karyopharm Therapeutics (Advisor); Bristol Myers Squibb, Genentech, Janssen Pharmaceuticals, Legend Biotech, Sanofi (Consultant).
María-Victoria Mateos, MD, PhD, has relevant financial relationships with Amgen, Bristol Myers Squibb, GSK, Janssen Pharmaceuticals, Oncopeptides, Inc., Pfizer, Sanofi, Seagen, Inc. (Advisor); Amgen, Bristol Myers Squibb, GSK, Janssen Pharmaceuticals, Pfizer, Sanofi, Takeda (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant
financial relationship(s) with ineligible companies to disclose with the
exception of Sara Fagerlie, PhD, CHCP, medical writer, who had a relevant
financial relationship with Adaptive Biotechnologies (Consultant).
This relevant financial relationship has been divested.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 1.0 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at Accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM AND
YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
1.0 ANCC Contact Hour(s)
Expires: January 29, 2024
Provided By
RMEI Medical Education, LLC
Target Audience
Medical oncologists, hematologists, hematologist-oncologists, pathologists, and oncology nurses
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Select an appropriate B cell maturation antigen (BCMA) targeted therapy among approved options for patients with relapsed/refractory (R/R) multiple myeloma (MM)
- Integrate novel BCMA-targeted therapies into the treatment paradigm of R/R MM, with an emphasis on bispecific antibodies
- Manage adverse events (AEs) associated with BCMA-directed therapies in patients with R/R MM
Activity Description
The advent of BCMA-directed therapy fills a significant gap in the treatment of relapsed/refractory multiple myeloma. As the field rapidly evolves, clinicians are challenged to navigate an increasingly complex therapeutic landscape. In this clinically relevant, high-level activity, Dr. Sundar Jagannath, Dr. María-Victoria Mateos, and Dr. James Hoffman provide privileged insights into optimal selection and integration of BCMA-directed therapies, particularly bispecific antibodies, to maximize patient outcomes.
Chair
Chair, Multiple Myeloma
Professor, Medicine
Icahn School of Medicine at Mount Sinai
Director, Multiple Myeloma Center of Excellence
Tisch Cancer Center Institute
Editor-in-Chief, Clinical Lymphoma, Myeloma & Leukemia
Mount Sinai Hospital
New York, NY
Faculty
Associate Professor, Clinical Medicine
Division of Myeloma (Hematology)
Sylvester Comprehensive Cancer Center (SCCC)
University of Miami
Miami, FL
Associate Professor, Hematology
Director, Myeloma Program
University Hospital of Salamanca
Salamanca, Spain
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
James Hoffman, MD, has relevant financial relationships with Bristol Myers Squibb (Speaker/Speaker’s Bureau).
Sundar Jagannath, MD, FASCO, has relevant financial relationships with Epizyme, Karyopharm Therapeutics (Advisor); Bristol Myers Squibb, Genentech, Janssen Pharmaceuticals, Legend Biotech, Sanofi (Consultant).
María-Victoria Mateos, MD, PhD, has relevant financial relationships with Amgen, Bristol Myers Squibb, GSK, Janssen Pharmaceuticals, Oncopeptides, Inc., Pfizer, Sanofi, Seagen, Inc. (Advisor); Amgen, Bristol Myers Squibb, GSK, Janssen Pharmaceuticals, Pfizer, Sanofi, Takeda (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant
financial relationship(s) with ineligible companies to disclose with the
exception of Sara Fagerlie, PhD, CHCP, medical writer, who had a relevant
financial relationship with Adaptive Biotechnologies (Consultant).
This relevant financial relationship has been divested.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 1.0 contact hour(s).
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at Accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM AND
YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Current and Emerging Therapies for Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
StartActivity Details
Expires: September 22, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Transplantation, hematology, and hematology/oncology clinicians engaged in the care of patients with GVHD.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Utilize available therapeutic strategies for the prevention and treatment of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (alloHSCT)
- Implement current and emerging strategies to address unmet needs in the management of steroid-refractory acute GVHD in allogeneic HSCT
Activity Description
Allogeneic HSCT is a revolutionary therapeutic discovery, yet despite advances, the procedure still carries substantial risk for complications and death. Even with prophylactic measures, many patients will go on to develop acute graft-versus-host disease (aGVHD). While there are several agents available for the prevention and treatment of aGVHD, there are still many unmet needs. In this Clinical Reflections® activity, learners will be presented with 2 cases of aGVHD and challenged by expert faculty to reflect back on how they could have been better managed. Faculty will then discuss current guidelines; prevention and treatment options; and emerging agents for prevention, first-line therapy, and steroid-refractory aGVHD.
Faculty
Associate Professor, Medicine
Hematology/Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Assistant Professor, Pediatrics
Harvard Medical School
Medical Director, Clinical Research and Clinical Development
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, MA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Christine N. Duncan, MD, has relevant financial relationships with bluebird bio, Inc., Jazz Pharmaceuticals, Magenta Therapeutics, Novartis, Omeros, Tome Biosciences (Consultant).
Doris M. Ponce, MD, has relevant financial relationships with Incyte Corporation, Kadmon Corporation (Advisor); CareDx, Ceramedix, Evive Biotech, Kadmon Corporation (Consultant); Incyte Corporation (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support of improving
patient care, RMEI Medical Education, LLC is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from CSL Behring LLC.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Activity Details
Expires: September 22, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Transplantation, hematology, and hematology/oncology clinicians engaged in the care of patients with GVHD.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Utilize available therapeutic strategies for the prevention and treatment of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (alloHSCT)
- Implement current and emerging strategies to address unmet needs in the management of steroid-refractory acute GVHD in allogeneic HSCT
Activity Description
Allogeneic HSCT is a revolutionary therapeutic discovery, yet despite advances, the procedure still carries substantial risk for complications and death. Even with prophylactic measures, many patients will go on to develop acute graft-versus-host disease (aGVHD). While there are several agents available for the prevention and treatment of aGVHD, there are still many unmet needs. In this Clinical Reflections® activity, learners will be presented with 2 cases of aGVHD and challenged by expert faculty to reflect back on how they could have been better managed. Faculty will then discuss current guidelines; prevention and treatment options; and emerging agents for prevention, first-line therapy, and steroid-refractory aGVHD.
Faculty
Associate Professor, Medicine
Hematology/Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Assistant Professor, Pediatrics
Harvard Medical School
Medical Director, Clinical Research and Clinical Development
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, MA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Christine N. Duncan, MD, has relevant financial relationships with bluebird bio, Inc., Jazz Pharmaceuticals, Magenta Therapeutics, Novartis, Omeros, Tome Biosciences (Consultant).
Doris M. Ponce, MD, has relevant financial relationships with Incyte Corporation, Kadmon Corporation (Advisor); CareDx, Ceramedix, Evive Biotech, Kadmon Corporation (Consultant); Incyte Corporation (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support of improving
patient care, RMEI Medical Education, LLC is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from CSL Behring LLC.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.